Pharmaceutical Technology2d
Tevimbra by BeiGene for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.
Pharm Exec6d
FDA Approves BeiGene’s Tevimbra for Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
Approval of Tevimbra was supported by the RATIONALE-305 Phase III trial, which demonstrated a significant overall survival benefit in patients with unresectable or metastatic HER2-negative gastric or ...
The American Journal of Managed Care5d
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...
The Play On Summit Therapeutics
Explore Summit Therapeutics' stock performance and financial health amid ivonescimab concerns, and learn how to strategically ...
Targeted Oncology4d
FDA’s December 2024 Oncology Approvals and Designations
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Targeted Oncology3d
The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers
The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...
Managed Healthcare Executive1d
Progress Made for Gastric Cancer with FDA Approval of Tevimbra
Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of ...
precisionmedicineonline5d
BeiGene Nabs FDA Approval for Tevimbra With Chemo in First-Line PD-L1-Positive Gastric Cancer
Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.